Incidental discovery of acute myeloid leukemia during liquid biopsy of a lung cancer patient
Open Access
- 22 June 2022
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 8 (4), a006201
- https://doi.org/10.1101/mcs.a006201
Abstract
Liquid biopsy is considered an alternative to standard next-generation sequencing (NGS) of solid tumor samples when biopsy tissue is inadequate for testing or when testing of a peripheral blood sample is preferred. A common assumption of liquid biopsies is that the NGS data obtained on circulating cell-free DNA is a high-fidelity reflection of what would be found by solid tumor testing. Here, we describe a case that challenges this widely held assumption. A patient diagnosed with lung carcinoma showed pathogenic IDH1 and TP53 mutations by liquid biopsy NGS at an outside laboratory. Subsequent in-house NGS of a metastatic lymph node fine-needle aspiration (FNA) sample revealed two pathogenic EGFR mutations. Morphologic and immunophenotypic assessment of the patient's blood sample identified acute myeloid leukemia, with in-house NGS confirming and identifying pathogenic IDH1, TP53, and BCOR mutations, respectively. This case, together with a few similar reports, demonstrates that caution is needed when interpreting liquid biopsy NGS results, especially if they are inconsistent with the presumptive diagnosis. Our case suggests that routine parallel sequencing of peripheral white blood cells would substantially increase the fidelity of the obtained liquid biopsy results.Keywords
This publication has 42 references indexed in Scilit:
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsThe Lancet Oncology, 2015
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNature Medicine, 2014
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAClinical Cancer Research, 2014
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- TP53 Mutations in Nonsmall Cell Lung CancerJournal of Biomedicine and Biotechnology, 2011
- Metachronous and synchronous presentation of acute myeloid leukemia and lung cancerLeukemia Research, 2009
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerThe New England Journal of Medicine, 2009
- Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung CancerClinical Cancer Research, 2009
- Multiple Primary Malignant NeoplasmsAmerican Journal of Clinical Oncology, 2003
- Clinical Implication of p53 Mutation in Lung CancerMolecular Biotechnology, 2003